REQUESTING THE AUDITOR TO ASSESS BOTH THE SOCIAL AND FINANCIAL EFFECTS OF PROPOSED MANDATED HEALTH INSURANCE COVERAGE FOR A PERCENTAGE OF THE COSTS OF INTRAVENOUS KETAMINE THERAPY TO TREAT DEPRESSION.

This Senate Resolution (SR 4) requests Hawaii's Auditor to analyze the social and financial impacts of mandating health insurance coverage for a portion of intravenous ketamine therapy costs to treat depression. It specifically requires this assessment under Hawaii Revised Statutes §23-51 before any bill mandating such coverage (like the referenced Senate Bill No. [blank]) can be considered. The Auditor must submit a report to the Legislature by February 2026, detailing findings and recommendations. This resolution does not create new policy but is a procedural step required before potential future legislation on ketamine therapy coverage. It directly affects the legislative process for any future bill proposing this coverage mandate.